Cancer Research Annual Meeting 2010 EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Del Bufalo, D.
Right arrow Articles by Milella, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Del Bufalo, D.
Right arrow Articles by Milella, M.
[Cancer Research 66, 5549-5554, June 1, 2006]
© 2006 American Association for Cancer Research

Priority Reports

Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus

Donatella Del Bufalo1, Ludovica Ciuffreda2, Daniela Trisciuoglio1, Marianna Desideri1, Francesco Cognetti2, Gabriella Zupi1 and Michele Milella2

1 Laboratory of Experimental Chemotherapy and 2 Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy

Requests for reprints: Michele Milella, Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy. Phone: 39-06-5266-6919/6774; Fax: 39-06-5266-5637; E-mail: milella{at}ifo.it.

Mammalian target of rapamycin (mTOR) is increasingly recognized as a master regulator of fundamental cellular functions, whose deregulation may underlie neoplastic transformation and progression. Hence, mTOR has recently emerged as a promising target for therapeutic anticancer interventions in several human tumors, including breast cancer. Here, we investigated the antiangiogenic potential of temsirolimus (also known as CCI-779), a novel mTOR inhibitor currently in clinical development for the treatment of breast cancer and other solid tumors. Consistent with previous reports, sensitivity to temsirolimus-mediated growth inhibition varied widely among different breast cancer cell lines and was primarily due to inhibition of proliferation with little, if any, effect on apoptosis induction. In the HER-2 gene–amplified breast cancer cell line BT474, temsirolimus inhibited vascular endothelial growth factor (VEGF) production in vitro under both normoxic and hypoxic conditions through inhibition of hypoxia-stimulated hypoxia-inducible factor (HIF)-1{alpha} expression and transcriptional activation. Interestingly, these effects were also observed in the MDA-MB-231 cell line, independent of its inherent sensitivity to the growth-inhibitory effects of temsirolimus. A central role for mTOR (and the critical regulator of cap-dependent protein translation, eIF4E) in the regulation of VEGF production by BT474 cells was further confirmed using a small interfering RNA approach to silence mTOR and eIF4E protein expression. In addition to its effect on HIF-1{alpha}–mediated VEGF production, temsirolimus also directly inhibited serum- and/or VEGF-driven endothelial cell proliferation and morphogenesis in vitro and vessel formation in a Matrigel assay in vivo. Overall, these results suggest that antiangiogenic effects may substantially contribute to the antitumor activity observed with temsirolimus in breast cancer. (Cancer Res 2006; 66(11): 5549-54)




This article has been cited by other articles:


Home page
 Therapeutic Advances in Medical OncologyHome page
T. B. Dorff, A. Goldkorn, and D. I. Quinn
Review: Targeted therapy in renal cancer
Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 183 - 205.
[Abstract] [PDF]

Home page
 JCOHome page
S. L. Ellard, M. Clemons, K. A. Gelmon, B. Norris, H. Kennecke, S. Chia, K. Pritchard, A. Eisen, T. Vandenberg, M. Taylor, et al.
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
J. Clin. Oncol., September 20, 2009; 27(27): 4536 - 4541.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
N. Normanno, A. Morabito, A. De Luca, M. C. Piccirillo, M. Gallo, M. R Maiello, and F. Perrone
Target-based therapies in breast cancer: current status and future perspectives
Endocr. Relat. Cancer, September 1, 2009; 16(3): 675 - 702.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Yu, L. Toral-Barza, C. Shi, W.-G. Zhang, J. Lucas, B. Shor, J. Kim, J. Verheijen, K. Curran, D. J. Malwitz, et al.
Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Cancer Res., August 1, 2009; 69(15): 6232 - 6240.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
O. Ekshyyan, Y. Rong, X. Rong, K. M. Pattani, F. Abreo, G. Caldito, J. K. S. Chang, F. Ampil, J. Glass, and C.-A. O. Nathan
Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma
Mol. Cancer Ther., August 1, 2009; 8(8): 2255 - 2265.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Brepoels, S. Stroobants, G. Verhoef, T. De Groot, L. Mortelmans, and C. De Wolf-Peeters
18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model
J. Nucl. Med., July 1, 2009; 50(7): 1102 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. W. Ronellenfitsch, D. P. Brucker, M. C. Burger, S. Wolking, F. Tritschler, J. Rieger, W. Wick, M. Weller, and J. P. Steinbach
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death
Brain, June 1, 2009; 132(6): 1509 - 1522.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
R. Marone, D. Erhart, A. C. Mertz, T. Bohnacker, C. Schnell, V. Cmiljanovic, F. Stauffer, C. Garcia-Echeverria, B. Giese, S.-M. Maira, et al.
Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Mol. Cancer Res., April 1, 2009; 7(4): 601 - 613.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. A. Lane, J. M. Wood, P. M.J. McSheehy, P. R. Allegrini, A. Boulay, J. Brueggen, A. Littlewood-Evans, S.-M. Maira, G. Martiny-Baron, C. R. Schnell, et al.
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Clin. Cancer Res., March 1, 2009; 15(5): 1612 - 1622.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Yu, J. Wang, Y. Chen, X. Wang, J. Pan, G. Li, Z. Jia, Q. Li, J. C. Yao, and K. Xie
Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer
Clin. Cancer Res., March 1, 2009; 15(5): 1821 - 1829.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Hartford, A. A. Desai, L. Janisch, T. Karrison, V. M. Rivera, L. Berk, J. W. Loewy, H. Kindler, W. M. Stadler, H. L. Knowles, et al.
A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
Clin. Cancer Res., February 15, 2009; 15(4): 1428 - 1434.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot
Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis
Clin. Cancer Res., February 15, 2009; 15(4): 1297 - 1307.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. D. Murphy, A. C. Spalding, Y. R. Somnay, S. Markwart, M. E. Ray, and D. A. Hamstra
Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature
Clin. Cancer Res., January 15, 2009; 15(2): 589 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Ackler, Y. Xiao, M. J. Mitten, K. Foster, A. Oleksijew, M. Refici, S. Schlessinger, B. Wang, S. R. Chemburkar, J. Bauch, et al.
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
Mol. Cancer Ther., October 1, 2008; 7(10): 3265 - 3274.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Oncologist, October 1, 2008; 13(10): 1084 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. C. Yao, A. T. Phan, D. Z. Chang, R. A. Wolff, K. Hess, S. Gupta, C. Jacobs, J. E. Mares, A. N. Landgraf, A. Rashid, et al.
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
J. Clin. Oncol., September 10, 2008; 26(26): 4311 - 4318.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bellmunt, C. Szczylik, J. Feingold, A. Strahs, and A. Berkenblit
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
Ann. Onc., August 1, 2008; 19(8): 1387 - 1392.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Garcia and D. Danielpour
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Mol. Cancer Ther., June 1, 2008; 7(6): 1347 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Vazquez-Martin, C. Oliveras-Ferraros, R. Colomer, J. Brunet, and J. A. Menendez
Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells
Ann. Onc., June 1, 2008; 19(6): 1097 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Jiang, H. Kenerson, L. Aicher, R. Miyaoka, J. Eary, J. Bissler, and R. S. Yeung
The Tuberous Sclerosis Complex Regulates Trafficking of Glucose Transporters and Glucose Uptake
Am. J. Pathol., June 1, 2008; 172(6): 1748 - 1756.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Shor, W.-G. Zhang, L. Toral-Barza, J. Lucas, R. T. Abraham, J. J. Gibbons, and K. Yu
A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
Cancer Res., April 15, 2008; 68(8): 2934 - 2943.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. Boni, C. Leister, J. Burns, M. Cincotta, B. Hug, and L. Moore
Pharmacokinetic Profile of Temsirolimus With Concomitant Administration of Cytochrome P450-Inducing Medications
J. Clin. Pharmacol., November 1, 2007; 47(11): 1430 - 1439.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, G. R. Hudes, B. D. Curti, D. F. McDermott, B. J. Escudier, S. Negrier, B. Duclos, L. Moore, T. O'Toole, J. P. Boni, et al.
Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma
J. Clin. Oncol., September 1, 2007; 25(25): 3958 - 3964.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. D. Mosley, J. T. Poirier, D. D. Seachrist, M. D. Landis, and R. A. Keri
Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
Mol. Cancer Ther., August 1, 2007; 6(8): 2188 - 2197.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, et al.
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
N. Engl. J. Med., May 31, 2007; 356(22): 2271 - 2281.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.